Anti-Human CD70 Recombinant Antibody (Vorsetuzumab)

Customer Review

There are currently no Customer reviews or questions for TAB-H76. Click the button above to contact us or submit your feedback about this product.

Jessica Hill
22.Feb,23

Excellent for CD70 Studies

The Anti-Human CD70 Therapeutic Antibody (vorsetuzumab) has been excellent for our CD70 detection assays. Its specificity and sensitivity are top-notch, providing clear and reliable results. This antibody has significantly improved the accuracy of our experiments and saved us a lot of troubleshooting time.

David Adams
29.May,22

Reliable in Immunoassays

We incorporated this antibody into our immunoassays, and it has been a great asset. The specificity for CD70 is precise, allowing for accurate detection and analysis. The reliable performance has made it an invaluable tool in our lab.

Megan Martinez
13.Aug,21

Consistent High-Quality Results

This antibody has proven to be consistent and reliable in our assays. The high-quality, reproducible results have significantly improved our experiments, making it a crucial part of our research toolkit. The strong affinity and specificity for CD70 have been particularly beneficial.

Q&As

1. Is the anti-Human CD70 therapeutic antibody Vorsetuzumab suitable for use in Western blotting?

   A: Yes, the anti-Human CD70 therapeutic antibody Vorsetuzumab (TAB-H76) is suitable for use in Western blotting. It provides specific binding to CD70, allowing for reliable detection in Western blot assays.

2. What are the storage recommendations for the anti-Human CD70 therapeutic antibody Vorsetuzumab?

   A: The recommended storage condition for the anti-Human CD70 therapeutic antibody Vorsetuzumab (TAB-H76) is at -20°C or lower. For short-term storage, it can be kept at 2-8°C. To ensure stability, avoid repeated freeze-thaw cycles.

3. Can the anti-Human CD70 therapeutic antibody Vorsetuzumab be used in immunoprecipitation assays?

   A: Yes, the anti-Human CD70 therapeutic antibody Vorsetuzumab (TAB-H76) can be used in immunoprecipitation assays. It provides specific binding to CD70, enabling the successful precipitation of the target protein from complex mixtures.

4. Is the anti-Human CD70 therapeutic antibody Vorsetuzumab effective in ELISA applications?

   A: Yes, the anti-Human CD70 therapeutic antibody Vorsetuzumab (TAB-H76) is effective in ELISA applications. It has been validated for use in such assays and provides reliable detection of CD70.

5. What is the optimal dilution for using the anti-Human CD70 therapeutic antibody Vorsetuzumab in immunofluorescence?

   A: The optimal dilution for using the anti-Human CD70 therapeutic antibody Vorsetuzumab (TAB-H76) in immunofluorescence is typically 1:100 to 1:500. It is advisable to perform a dilution series to determine the best working concentration for your specific experimental conditions.

View the frequently asked questions answered by Creative Biolabs Support.

Citations

1. Shiomi, Mayu, et al. "CD70 antibody-drug conjugate: A potential novel therapeutic agent for ovarian cancer." Cancer Science 112.9 (2021): 3655-3668. https://doi.org/10.1111/cas.15027
   This study focused on evaluating the cytotoxic effects of a CD70 antibody-drug conjugate (CD70-ADC) on ovarian cancer cells both in vitro and in vivo. The researchers assessed CD70 expression in ovarian cancer cell lines and clinical samples. They found that CD70 expression was significantly higher in ovarian cancer cells exposed to cisplatin, particularly in those with resistance to the drug. The CD70-ADC was developed using an anti-CD70 monoclonal antibody linked to monomethyl auristatin F (MMAF). The study demonstrated that CD70-ADC had a substantial inhibitory effect on the growth of CD70-expressing ovarian cancer cells, suggesting its potential as a novel therapeutic agent for treating ovarian cancer.
   Creative Biolabs played a crucial role in this research by providing the anti-CD70 monoclonal antibody, vorsetuzumab (Cat#: TAB-H76), which was essential for creating the CD70-ADC. This antibody was conjugated with MMAF to produce the CD70-ADC used in the experiments. The specific anti-CD70 antibody provided by Creative Biolabs was vital for targeting CD70-expressing ovarian cancer cells and demonstrating the therapeutic potential of CD70-ADC in inhibiting tumor growth in both in vitro and in vivo models. The provision of this high-quality monoclonal antibody enabled the researchers to effectively explore the cytotoxic effects and therapeutic implications of CD70-ADC in ovarian cancer treatment.

Cite This Product

To accurately reference this product in your publication, please use the following citation information:

(Creative Biolabs Cat# TAB-H76, RRID: AB_3112047)

Submit Your Publication

Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.

Biosimilar Overview

Please refer to Vorsetuzumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Vorsetuzumab.

Downloadable Resources

Download resources about recombinant antibody development and antibody engineering to boost your research.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Datasheet

MSDS

COA

To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.

Protocol & Troubleshooting

We have outlined the assay protocols, covering reagents, solutions, procedures, and troubleshooting tips for common issues in order to better assist clients in conducting experiments with our products. View the full list of Protocol & Troubleshooting.

See other products for "Vorsetuzumab"

Afuco™ Anti-CD70 ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-H76)

This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant Humanized (from mouse) antibody to Human CD70. It is a monoclonal antibody designed for the treatment of cancer.

See other products for "CD70"

Select a product category from the dropdown menu below to view related products.